What exactly changed in the XTNT analyst rating on March 18, 2026?

Craig-Hallum on March 18, 2026 maintained a **Buy** on XTNT but lowered its price target due to expected EBITDA margin compression. The firm kept its positive stance while signaling weaker near-term profitability for Xtant Medical Holdings, Inc.

Does the price target cut count as an XTNT downgrade?

No. Craig-Hallum did not change the rating; it kept **Buy**. The firm reduced the price target, which tightens upside expectations but is not a formal rating downgrade in the XTNT analyst rating.

How should investors interpret the XTNT analyst rating now?

Treat the maintained **Buy** as continued confidence from Craig-Hallum, but expect pressure from margin risk. Monitor EBITDA trends and upcoming earnings to see if the XTNT analyst rating outlook improves or deteriorates.

Where can I read the original analyst note on the XTNT analyst rating?

The Craig-Hallum update was summarized on StreetInsider. See the coverage at [StreetInsider](https://www.streetinsider.com/Analyst+Comments/Craig-Hallum+lowers+PT+on+Xtant+Medical+%28XTNT%29+on+expected+EBITDA+margin+compression/26181014.html) for the full text.

Analyst Ratings

Craig-Hallum Maintains Buy on XTNT Xtant Medical Holdings, Inc. March 2026

ByDanny Kontos March 19, 2026

Craig-Hallum on March 18, 2026 at 09:10 AM maintained a Buy on XTNT while lowering its price target. The XTNT analyst rating update centers on expected EBITDA margin compression as the core reason for the price target cut. The note appeared on StreetInsider and shows the firm keeps conviction in Xtant Medical Holdings, Inc.’s recovery but sees tighter near-term margins. The market reacted modestly, with a -0.87% change equal to $-0.01 at the time of the release.